Genmab As (GNMSF) Forecasted to Earn FY2018 Earnings of $4.27 Per Share

Genmab As (OTCMKTS:GNMSF) – Research analysts at Jefferies Group decreased their FY2018 earnings per share (EPS) estimates for Genmab As in a report issued on Friday. Jefferies Group analyst P. Welford now forecasts that the company will post earnings of $4.27 per share for the year, down from their prior estimate of $4.34.

A number of other analysts also recently issued reports on GNMSF. JPMorgan Chase & Co. downgraded shares of Genmab As from an “overweight” rating to a “neutral” rating in a report on Friday, October 6th. Zacks Investment Research downgraded shares of Genmab As from a “hold” rating to a “sell” rating in a report on Monday, November 13th.

Genmab As (GNMSF) traded up $9.50 during midday trading on Monday, reaching $185.75. 2,530 shares of the company were exchanged, compared to its average volume of 1,447. Genmab As has a 1-year low of $163.00 and a 1-year high of $239.75. The stock has a market capitalization of $10,780.00 and a P/E ratio of 60.99.

COPYRIGHT VIOLATION NOTICE: “Genmab As (GNMSF) Forecasted to Earn FY2018 Earnings of $4.27 Per Share” was first published by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.themarketsdaily.com/2018/01/10/genmab-as-gnmsf-forecasted-to-earn-fy2018-earnings-of-4-27-per-share.html.

About Genmab As

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer in Denmark and internationally. The company markets Arzerra, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia (CCL); and DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM).

Receive News & Ratings for Genmab As Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab As and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply